Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT6A | Q92794 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29459930 | 0.83 | MRGPRX4 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL496275 | 0.83 | MRGPRX4 (0.61) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL2095288 | 0.81 | KAT6A (0.51) | KAT6AMAOBTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL690501 | 0.81 | KAT6A (0.54) | KAT6AMAOBTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL4420270 | 0.81 | MAOB (0.52) | KAT6AMAOBTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30668192 | 0.80 | KAT6A (0.57) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL22954042 | 0.80 | KAT6A (0.57) | KAT6ATAS1R3TAS1R1TAS1R2MRGPRX4 | |
| SCHEMBL28186416 | 0.80 | EPHX2 (0.49) | MRGPRX4 | |
| SCHEMBL10561497 | 0.80 | KAT6A (0.52) | KAT6AMAOBTAS1R3TAS1R1TAS1R2 | |
| SCHEMBL28208860 | 0.80 | KAT6A (0.52) | KAT6AMAOBTAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313539-A1 | Alpha, Beta-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES (CN) | 2025-10-09 | — | — | US | disclosed |
| EP-4553069-A1 | ALPHA,ß-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790041-A | Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2025-04-08 | — | — | CN | disclosed |
| CN-115286625-B | Glutaminase allosteric site covalent inhibitor and preparation method and application thereof | 浙江工业大学 | 2025-03-25 | — | — | CN | disclosed |
| CN-117402123-A | Alpha, beta-unsaturated amide compounds, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-01-16 | — | — | CN | disclosed |
| CN-115286625-A | Glutaminase allosteric site covalent inhibitor and preparation method and application thereof | 浙江工业大学 | 2022-11-04 | — | — | CN | disclosed |
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313539-A1 | Alpha, Beta-UNSATURATED AMIDE COMPOUND, AND PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | DEGS1, ACAD11, HADHA | KAT6A 2875/4885MAOB 1688/4885TAS1R3 3635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.